ID

39891

Beschreibung

Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir -Boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)- Naive Adults or Adults Recommencing ART.; ODM derived from: https://clinicaltrials.gov/show/NCT01258439

Link

https://clinicaltrials.gov/show/NCT01258439

Stichworte

Versionen (1)
  1. 29.02.20 29.02.20 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

29. Februar 2020

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility HIV NCT01258439

Englisch

Eligibility HIV NCT01258439

1 Formulare  
  1. StudyEvent: Eligibility
    1. Eligibility HIV NCT01258439
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
provision of signed, informed consent
Beschreibung

Informed Consent

Datentyp

boolean

Alias
UMLS CUI [1]
C0021430
age >18 years
Beschreibung

Age

Datentyp

boolean

Alias
UMLS CUI [1]
C0001779
hiv infection documented by hiv antibody test and western blot prior to study entry
Beschreibung

HIV Infections | HIV Antibody Measurement | Western blot for HIV

Datentyp

boolean

Alias
UMLS CUI [1]
C0019693
UMLS CUI [2]
C3714540
UMLS CUI [3]
C0860963
no previous art or no art for 6 months prior to randomisation
Beschreibung

Antiretroviral therapy Absent

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1963724
UMLS CUI [1,2]
C0332197
cd4+ count of <500 cells/mm or viral load >10,000 copies/ml within 60 days prior to randomisation
Beschreibung

CD4+ Count | Viral load measurement

Datentyp

boolean

Alias
UMLS CUI [1]
C0243009
UMLS CUI [2]
C1261478
no genotypic resistance to raltegravir, tenofovir/emtricitabine, darunavir, ritonavir
Beschreibung

Absence Resistance Genotypic Raltegravir | Absence Resistance Genotypic Tenofovir | Absence Resistance Genotypic Emtricitabine | Absence Resistance Genotypic Darunavir | Absence Resistance Genotypic Ritonavir

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0332197
UMLS CUI [1,2]
C1514892
UMLS CUI [1,3]
C0017431
UMLS CUI [1,4]
C1871526
UMLS CUI [2,1]
C0332197
UMLS CUI [2,2]
C1514892
UMLS CUI [2,3]
C0017431
UMLS CUI [2,4]
C0384228
UMLS CUI [3,1]
C0332197
UMLS CUI [3,2]
C1514892
UMLS CUI [3,3]
C0017431
UMLS CUI [3,4]
C0909839
UMLS CUI [4,1]
C0332197
UMLS CUI [4,2]
C1514892
UMLS CUI [4,3]
C0017431
UMLS CUI [4,4]
C1435444
UMLS CUI [5,1]
C0332197
UMLS CUI [5,2]
C1514892
UMLS CUI [5,3]
C0017431
UMLS CUI [5,4]
C0292818
body mass index less than 30kg/m2
Beschreibung

Body mass index

Datentyp

boolean

Alias
UMLS CUI [1]
C1305855
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
primary hiv infection within the last 6 months
Beschreibung

Primary HIV infection Recent

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1142553
UMLS CUI [1,2]
C0332185
active infection or opportunistic illness within the previous 30 days
Beschreibung

Communicable Disease Recent | Opportunistic Infection Recent

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0009450
UMLS CUI [1,2]
C0332185
UMLS CUI [2,1]
C0029118
UMLS CUI [2,2]
C0332185
use of any medication contra-indicated with ritonavir-boosted darunavir or raltegravir
Beschreibung

Pharmaceutical Preparation Contraindicated Darunavir+Ritonavir | Pharmaceutical Preparation Contraindicated Raltegravir

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C1444657
UMLS CUI [1,3]
C1976853
UMLS CUI [2,1]
C0013227
UMLS CUI [2,2]
C1444657
UMLS CUI [2,3]
C1871526
use of lipid-lowering therapy
Beschreibung

Lipid-lowering therapy

Datentyp

boolean

Alias
UMLS CUI [1]
C0585943
diabetes mellitus (fasting glucose >7.0mml/l or a prior diagnosis of diabetes)
Beschreibung

Diabetes Mellitus | Glucose measurement, fasting

Datentyp

boolean

Alias
UMLS CUI [1]
C0011849
UMLS CUI [2]
C0202045
use of oral prednisolone > 7.5mg daily or equivalent
Beschreibung

Oral prednisolone U/day | Equivalent

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0358513
UMLS CUI [1,2]
C0456683
UMLS CUI [2]
C0205163
pregnancy or breast feeding
Beschreibung

Pregnancy | Breast Feeding

Datentyp

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
proven hypersensitivity to one or more components of the study meal
Beschreibung

Hypersensitivity Component Study Meal

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C1705248
UMLS CUI [1,3]
C0008972
UMLS CUI [1,4]
C1998602
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility HIV NCT01258439

1 Formulare
  1. StudyEvent: Eligibility
    1. Eligibility HIV NCT01258439
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Informed Consent
Item
provision of signed, informed consent
boolean
C0021430 (UMLS CUI [1])
Age
Item
age >18 years
boolean
C0001779 (UMLS CUI [1])
HIV Infections | HIV Antibody Measurement | Western blot for HIV
Item
hiv infection documented by hiv antibody test and western blot prior to study entry
boolean
C0019693 (UMLS CUI [1])
C3714540 (UMLS CUI [2])
C0860963 (UMLS CUI [3])
Antiretroviral therapy Absent
Item
no previous art or no art for 6 months prior to randomisation
boolean
C1963724 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
CD4+ Count | Viral load measurement
Item
cd4+ count of <500 cells/mm or viral load >10,000 copies/ml within 60 days prior to randomisation
boolean
C0243009 (UMLS CUI [1])
C1261478 (UMLS CUI [2])
Absence Resistance Genotypic Raltegravir | Absence Resistance Genotypic Tenofovir | Absence Resistance Genotypic Emtricitabine | Absence Resistance Genotypic Darunavir | Absence Resistance Genotypic Ritonavir
Item
no genotypic resistance to raltegravir, tenofovir/emtricitabine, darunavir, ritonavir
boolean
C0332197 (UMLS CUI [1,1])
C1514892 (UMLS CUI [1,2])
C0017431 (UMLS CUI [1,3])
C1871526 (UMLS CUI [1,4])
C0332197 (UMLS CUI [2,1])
C1514892 (UMLS CUI [2,2])
C0017431 (UMLS CUI [2,3])
C0384228 (UMLS CUI [2,4])
C0332197 (UMLS CUI [3,1])
C1514892 (UMLS CUI [3,2])
C0017431 (UMLS CUI [3,3])
C0909839 (UMLS CUI [3,4])
C0332197 (UMLS CUI [4,1])
C1514892 (UMLS CUI [4,2])
C0017431 (UMLS CUI [4,3])
C1435444 (UMLS CUI [4,4])
C0332197 (UMLS CUI [5,1])
C1514892 (UMLS CUI [5,2])
C0017431 (UMLS CUI [5,3])
C0292818 (UMLS CUI [5,4])
Body mass index
Item
body mass index less than 30kg/m2
boolean
C1305855 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Primary HIV infection Recent
Item
primary hiv infection within the last 6 months
boolean
C1142553 (UMLS CUI [1,1])
C0332185 (UMLS CUI [1,2])
Communicable Disease Recent | Opportunistic Infection Recent
Item
active infection or opportunistic illness within the previous 30 days
boolean
C0009450 (UMLS CUI [1,1])
C0332185 (UMLS CUI [1,2])
C0029118 (UMLS CUI [2,1])
C0332185 (UMLS CUI [2,2])
Pharmaceutical Preparation Contraindicated Darunavir+Ritonavir | Pharmaceutical Preparation Contraindicated Raltegravir
Item
use of any medication contra-indicated with ritonavir-boosted darunavir or raltegravir
boolean
C0013227 (UMLS CUI [1,1])
C1444657 (UMLS CUI [1,2])
C1976853 (UMLS CUI [1,3])
C0013227 (UMLS CUI [2,1])
C1444657 (UMLS CUI [2,2])
C1871526 (UMLS CUI [2,3])
Lipid-lowering therapy
Item
use of lipid-lowering therapy
boolean
C0585943 (UMLS CUI [1])
Diabetes Mellitus | Glucose measurement, fasting
Item
diabetes mellitus (fasting glucose >7.0mml/l or a prior diagnosis of diabetes)
boolean
C0011849 (UMLS CUI [1])
C0202045 (UMLS CUI [2])
Oral prednisolone U/day | Equivalent
Item
use of oral prednisolone > 7.5mg daily or equivalent
boolean
C0358513 (UMLS CUI [1,1])
C0456683 (UMLS CUI [1,2])
C0205163 (UMLS CUI [2])
Pregnancy | Breast Feeding
Item
pregnancy or breast feeding
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Hypersensitivity Component Study Meal
Item
proven hypersensitivity to one or more components of the study meal
boolean
C0020517 (UMLS CUI [1,1])
C1705248 (UMLS CUI [1,2])
C0008972 (UMLS CUI [1,3])
C1998602 (UMLS CUI [1,4])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video